Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs)
Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs)
CLINICALTRIALS.GOV IDENTIFIER: NCT05997056
DRUG/TREATMENT:Â IV
PHASE:Â 2
STATUS: Recruiting
SPONSOR: Aadi Bioscience, Inc.
DESCRIPTION:
Dr. Scott Paulson Discusses the Nab-sirolimus Trial
This is a prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus and patients with functional or non-functional, well-differentiated, locally advanced unresectable in metastatic NETs of the GI tract, lung, or pancreas.Â
For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.
CONTACT/Principal Investigator:
Aadi Bioscience Medical Information
EMAIL: MedInfo@aadibio.com
PHONE: 1-888-246-2234
Locations:
Recruiting: United States at Texas Oncology in Dallas, Texas 75246Â
Contact: Christine Terraciano at christine.terraciano@usoncology.com
Principal Investigator: Scott Paulson, MD
Recruiting: United States at Hoag Memorial Hospital Presbyterian in Newport Beach, California 92663
Contact: Jason Ledesma at jason.ledesma@hoag.org
Principal investigator: Michael Demeure, MD
Not Yet Recruiting: United States, Denver, Colorado 80218